Headlines

PRE-MARKET INDIAN STOCKS NEWS: Ashoka Buildcon (ASBL IS) emerged as the lowest bidder for an NHAI project with an EPC bid of INR 14.65bln, excluding GST

Newsquawk Staff ·

Ashoka Buildcon (ASBL IS) - Co. emerged as the lowest bidder for an NHAI project with an EPC bid of INR 14.65bln, excluding GST. (Economic Times)

Bharti Airtel (BHARTI IS) - Co.'s Airtel Payments Bank Q2 (INR) net rose 139% Y/Y to 282mln, rev. rose 8.9% Y/Y to 8.76bln, while annualised revenue exceeded 35bln and annualised EBITDA approached 5bln. (Economic Times)

Biocon (BIOS IS) - Co. received EU approval for a biosimilar of pertuzumab. (Newswires)

Glenmark Pharmaceuticals (GNP IS) - Co.'s Ichnos Glenmark Innovation submitted an Investigational New Drug (IND) application to the US FDA for ISB 2301, an investigational cancer therapy designed to target three tumour-associated antigens and activate T cells and natural killer cells. (Moneycontrol)

HCL Technologies (HCLT IS) - Co. partnered with Cohere to develop sovereign AI solutions for enterprises and governments and will become a preferred global systems integrator partner in Canada and Germany. (Economic Times)

IIFL Finance (IIFL IS) - Fairfax India Holdings' subsidiary FIH Mauritius Investments plans to sell up to 56.5mln shares, representing approximately 13.25% of the Co.'s equity capital, through the secondary market. (Moneycontrol)

Other News

Tata Group - Former Tata Trusts trustee Darius Khambata reportedly questioned vice-chairmen Venu Srinivasan and Vijay Singh over their shifting position on the proposed Tata Sons listing and disputed claims that trustees were kept informed of discussions with the RBI. (Economic Times)

What it means

Pre-market wraps of this kind are a standing feature of the Indian session, and the single names tend to trade on their own idiosyncratic precedent rather than as a complex. L1 status on an NHAI EPC award, as with Ashoka Buildcon, is a familiar sequence in the roads space: the lowest-bid declaration typically moves the stock on the day, but the order only enters the book on formal award and letter of acceptance, and NHAI's historical pattern includes episodes where L1 bids were rejected as unreasonably low or renegotiated, so confirmation is the tell. The Bharti Airtel payments bank print and the Biocon EU biosimilar approval are incremental rather than thesis-changing items; EU biosimilar approvals have generally mattered for revenue timing rather than for the multiple. The IIFL Finance block is the cleanest price mechanic in the list, a defined secondary sale of a large stake by a long-standing holder, and blocks of that size have tended to cap the stock until absorbed, with the discount at which the trade clears being the key datum. The Tata Sons listing friction is a slow-burning governance story: the RBI-mandated listing timeline for upper-layer NBFCs is the structural backdrop, and public disagreement among trustees has historically prolonged rather than resolved the question. Nothing here is macro; the session read-through is stock-specific.

Related headlines